TMDX logo

TransMedics Group, Inc. Stock Price

NasdaqGM:TMDX Community·US$4.1b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 130 Fair Values set on narratives written by author

TMDX Share Price Performance

US$115.55
27.19 (30.77%)
US$141.91
Fair Value
US$115.55
27.19 (30.77%)
18.6% undervalued intrinsic discount
US$141.91
Fair Value
Price US$115.55
AnalystConsensusTarget US$141.91
AnalystLowTarget US$114.00
AnalystHighTarget US$170.00

TMDX Community Narratives

AnalystConsensusTarget·
Fair Value US$141.91 n/aintrinsic discount

TMDX: Expanding Organ Donor Pool And Clinical Trials Will Shape Future Direction

2users have liked this narrative
0users have commented on this narrative
55users have followed this narrative
AnalystLowTarget·
Fair Value US$114 1.4% overvalued intrinsic discount

Cost Pressures And Supply Risks Will Weaken Transplant Market Viability

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AnalystHighTarget·
Fair Value US$170 32.0% undervalued intrinsic discount

Transplant Logistics Will Meet Demand From An Aging World

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
US$114
1.4% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
17.98% p.a.
Profit Margin
13.4%
Future PE
43.88x
Share price in 2028
US$141.07

Snowflake Analysis

Solid track record with excellent balance sheet.

0 Risks
4 Rewards

TransMedics Group, Inc. Key Details

US$566.4m

Revenue

US$224.9m

Cost of Revenue

US$341.4m

Gross Profit

US$249.6m

Other Expenses

US$91.8m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
2.69
60.28%
16.20%
144.1%
View Full Analysis

About TMDX

Founded
1998
Employees
728
CEO
Waleed Hassanein
WebsiteView website
www.transmedics.com

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Recent TMDX News & Updates

Recent updates

No updates